US80105N1054 - ADR

**SNY** gets a fundamental rating of **6** out of 10. The analysis compared the fundamentals against 194 industry peers in the **Pharmaceuticals** industry. While **SNY** belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on **SNY**. Finally **SNY** also has an excellent dividend rating.

In the past year **SNY** was profitable.

Each year in the past 5 years **SNY** has been profitable.

In the past 5 years **SNY** always reported a positive cash flow from operatings.

The **Return On Assets** of **SNY** (**7.85%**) is better than **91.15%** of its industry peers.

The **Return On Equity** of **SNY** (**13.40%**) is better than **90.10%** of its industry peers.

The **Return On Invested Capital** of **SNY** (**12.90%**) is better than **91.67%** of its industry peers.

The **Average Return On Invested Capital** over the past 3 years for **SNY** is significantly below the industry average of **18.14%**.

The 3 year average ROIC (**7.48%**) for **SNY** is below the current ROIC(**12.90%**), indicating increased profibility in the last year.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 7.85% | ||

ROE | 13.4% | ||

ROIC | 12.9% |

ROA(3y)5.35%

ROA(5y)5.85%

ROE(3y)9.18%

ROE(5y)10.34%

ROIC(3y)7.48%

ROIC(5y)6.88%

With an excellent **Profit Margin** value of **14.17%**, **SNY** belongs to the best of the industry, outperforming **89.06%** of the companies in the same industry.

In the last couple of years the **Profit Margin** of **SNY** has remained more or less at the same level.

Looking at the **Operating Margin**, with a value of **23.81%**, **SNY** belongs to the top of the industry, outperforming **92.19%** of the companies in the same industry.

In the last couple of years the **Operating Margin** of **SNY** has grown nicely.

In the last couple of years the **Gross Margin** of **SNY** has remained more or less at the same level.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 23.81% | ||

PM (TTM) | 14.17% | ||

GM | 69.78% |

OM growth 3Y4.23%

OM growth 5Y5%

PM growth 3Y-29.3%

PM growth 5Y-0.74%

GM growth 3Y0.92%

GM growth 5Y0.41%

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so **SNY** is creating value.

The number of shares outstanding for **SNY** remains at a similar level compared to 1 year ago.

The number of shares outstanding for **SNY** has been increased compared to 5 years ago.

The Debt to FCF ratio of **SNY** is **2.55**, which is a good value as it means it would take **SNY**, **2.55** years of fcf income to pay off all of its debts.

The **Debt to FCF ratio** of **SNY** (**2.55**) is better than **92.19%** of its industry peers.

A Debt/Equity ratio of **0.22** indicates that **SNY** is not too dependend on debt financing.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.22 | ||

Debt/FCF | 2.55 | ||

Altman-Z | N/A |

ROIC/WACC1.81

WACC7.12%

With a **Current ratio** value of **1.28**, **SNY** is not doing good in the industry: **79.17%** of the companies in the same industry are doing better.

A Quick Ratio of **0.38** indicates that **SNY** may have some problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.28 | ||

Quick Ratio | 0.38 |

Measured over the past years, **SNY** shows a quite strong growth in **Earnings Per Share**. The EPS has been growing by **8.19%** on average per year.

Looking at the last year, **SNY** shows a small growth in **Revenue**. The Revenue has grown by **1.25%** in the last year.

EPS 1Y (TTM)-8.74%

EPS 3Y10.81%

EPS 5Y8.19%

EPS Q2Q%-17.59%

Revenue 1Y (TTM)1.25%

Revenue growth 3Y7.52%

Revenue growth 5Y5.42%

Sales Q2Q%2.37%

Based on estimates for the next years, **SNY** will show a small growth in **Earnings Per Share**. The EPS will grow by **6.98%** on average per year.

Based on estimates for the next years, **SNY** will show a small growth in **Revenue**. The Revenue will grow by **5.58%** on average per year.

EPS Next Y-5.41%

EPS Next 2Y4.07%

EPS Next 3Y5.48%

EPS Next 5Y6.98%

Revenue Next Year4.75%

Revenue Next 2Y5.85%

Revenue Next 3Y5.86%

Revenue Next 5Y5.58%

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

The **Price/Earnings** ratio is **11.94**, which indicates a very decent valuation of **SNY**.

With a **Price/Forward Earnings** ratio of **10.51**, the valuation of **SNY** can be described as very reasonable.

89.06% of the companies in the same industry are more expensive than **SNY**, based on the **Price/Forward Earnings** ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 11.94 | ||

Fwd PE | 10.51 |

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 15.94 | ||

EV/EBITDA | 5.81 |

PEG (NY)N/A

PEG (5Y)1.46

EPS Next 2Y4.07%

EPS Next 3Y5.48%

With a **Yearly Dividend Yield** of **4.01%**, **SNY** is a good candidate for dividend investing.

Compared to an average industry **Dividend Yield** of **4.02**, **SNY** pays a better dividend. On top of this **SNY** pays more dividend than 95.83% of the companies listed in the same industry.

Compared to an average S&P500 **Dividend Yield** of **2.33**, **SNY** pays a better dividend.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 4.01% |

The dividend of **SNY** has a limited annual growth rate of **3.31%**.

Dividend Growth(5Y)3.31%

Div Incr Years1

Div Non Decr Years1

DP44.9%

EPS Next 2Y4.07%

EPS Next 3Y5.48%

**SANOFI-ADR**

NASDAQ:SNY (7/17/2024, 2:29:05 PM)

**50.25**

**+0.2 (+0.4%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap125.73B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 4.01% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 11.94 | ||

Fwd PE | 10.51 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)1.46

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 7.85% | ||

ROE | 13.4% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 23.81% | ||

PM (TTM) | 14.17% | ||

GM | 69.78% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.55

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.22 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.28 | ||

Quick Ratio | 0.38 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-8.74%

EPS 3Y10.81%

EPS 5Y

EPS Q2Q%

EPS Next Y-5.41%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)1.25%

Revenue growth 3Y7.52%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y